← SynDRA
ALOGLIPTIN
SynDRA canonical compound SYN0006976 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | DPP4 |
|---|
| Mechanism of action | Dipeptidyl peptidase inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
Mechanisms of action (all sources)
- Dipeptidyl peptidase inhibitor
- DPP4 inhibitor
Drug classes
- Dipeptidyl-Peptidase IV Inhibitors
- Enzyme Inhibitors
- Hormones
- Hypoglycemic Agents
- Incretins
- Protease Inhibitors
- Dipeptidyl Peptidase 4 Inhibitors
- Dipeptidyl Peptidase 4 Inhibitor
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- vipidia
- alogliptin benzoate
- nesina
- Alogliptine
- Alogliptina
- Vipidia
- UNII-JHC049LO86
- alogliptina
- 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile
- SYR-322
- JHC049LO86
- (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile
- CHEBI:72323
- AK322010
- 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile
- Alogliptin [INN]
- Alogliptin (SYR-322)
- alogliptinum
- alogliptine
- HSDB 8203
- 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
- SYR322
- ALOGLIPTIN [MI]
- ALOGLIPTIN [VANDF]
- ALOGLIPTIN [WHO-DD]
- SCHEMBL121028
- CHEMBL376359
- GTPL6319
- BDBM16285
- HY-A0023A
- DTXSID90234130
- AMY22119
- EX-A5446
- Alogliptin pound SYR-322 pound(c)
- MFCD09833196
- s2868
- s5365
- ZINC14961096
Reported adverse events
- Hypersensitivity
- Stevens-Johnson syndrome
- Headache
- Nasopharyngitis
- Arthralgia
- Pancreatitis
- Abdominal discomfort
- Asthenia
- Back pain
- Flatulence
- Hypertension
- Nausea
Look up ALOGLIPTIN in the interactive SynDRA portal →